Published in EMBO J on August 15, 1997
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A (1998) 3.18
Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol (1999) 3.05
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. Biochem J (2003) 2.00
Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol (2002) 1.64
Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol Cell Biol (2001) 1.58
Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol (2005) 1.57
Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J (2000) 1.55
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J (1998) 1.49
Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol (1998) 1.30
Removal of the membrane-anchoring domain of epidermal growth factor leads to intracrine signaling and disruption of mammary epithelial cell organization. J Cell Biol (1998) 1.22
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol (1998) 1.19
ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci U S A (1998) 1.17
Characterization of the SP11/SCR high-affinity binding site involved in self/nonself recognition in brassica self-incompatibility. Plant Cell (2007) 1.07
The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J (1999) 1.06
The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer (2006) 1.01
The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A (1999) 1.00
Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer (1999) 0.96
Self-association of models of transmembrane domains of ErbB receptors in a lipid bilayer. Biophys J (2010) 0.94
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Front Oncol (2014) 0.94
Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. Biochem J (1998) 0.92
Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer (2009) 0.92
Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochem J (1999) 0.90
The interaction between the Drosophila secreted protein argos and the epidermal growth factor receptor inhibits dimerization of the receptor and binding of secreted spitz to the receptor. Mol Cell Biol (2000) 0.90
Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cell Adh Migr (2010) 0.89
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res (2010) 0.85
Oligomeric self-association of basic fibroblast growth factor in the absence of heparin-like glycosaminoglycans. Biochem J (1999) 0.84
Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell Int (2006) 0.84
The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. J Biol Chem (2015) 0.82
A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells. Exp Mol Med (2012) 0.81
Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology. PLoS One (2013) 0.81
Novel luciferase-based reporter system to monitor activation of ErbB2/Her2/neu pathway noninvasively during radiotherapy. Int J Radiat Oncol Biol Phys (2010) 0.79
Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search. Eur Biophys J (2008) 0.79
Cellular immunotherapy for pediatric solid tumors. Cytotherapy (2014) 0.77
ErbB2 dephosphorylation and anti-proliferative effects of neuregulin-1 in ErbB2-overexpressing cells; re-evaluation of their low-affinity interaction. Sci Rep (2013) 0.77
Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int Immunol (2011) 0.77
Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor. Protein Sci (2000) 0.75
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Kinetics of protein-protein association explained by Brownian dynamics computer simulation. Proc Natl Acad Sci U S A (1992) 6.71
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 5.91
Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol (1994) 5.24
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem (1991) 4.82
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A (1994) 4.51
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A (1987) 3.64
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 3.46
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry (1987) 3.20
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol (1995) 3.09
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J (1995) 2.87
Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell (1990) 2.58
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell (1989) 2.30
Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J (1997) 2.16
Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol (1995) 2.13
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Neu and its ligands: from an oncogene to neural factors. Bioessays (1993) 2.00
Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem (1996) 1.88
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem (1994) 1.88
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. Proc Natl Acad Sci U S A (1995) 1.73
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng (1990) 1.62
The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem (1996) 1.58
Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. Biochemistry (1993) 1.42
The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol (1990) 1.42
Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors (1994) 1.42
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem (1996) 1.38
Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A (1994) 1.24
ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia (1997) 1.20
Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases. J Biol Chem (1995) 1.19
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell (1995) 1.17
The structural basis for the specificity of epidermal growth factor and heregulin binding. J Biol Chem (1995) 1.14
Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. J Biol Chem (1995) 1.13
EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J Biol Chem (1991) 1.02
Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein. J Protein Chem (1989) 0.86
A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur J Cancer (1994) 0.86
Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. Cancer Treat Res (1994) 0.86
Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor. J Biol Chem (1996) 0.85
Multidomain binding of transforming growth factor alpha to the epidermal growth factor receptor. Biochemistry (1992) 0.78
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature (1986) 7.90
Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med (1965) 7.27
Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. Proc Natl Acad Sci U S A (1992) 6.86
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell (1999) 6.79
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
Expression of naphthalene oxidation genes in Escherichia coli results in the biosynthesis of indigo. Science (1983) 5.10
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry (1987) 3.94
CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature (1994) 3.70
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry (1987) 3.20
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
The localization of antigen in relation to specific antibody-producing cells. I. Use of a synthetic polypeptide [(T,G)-A--L] labelled with iodine-125. Immunology (1966) 3.09
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol (1995) 3.09
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem (2000) 3.06
Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem (1983) 2.94
Expression of epidermal growth factor receptors in human brain tumors. Cancer Res (1984) 2.83
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62
Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A (1998) 2.48
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol (2000) 2.47
The avian beta-adrenergic receptor: primary structure and membrane topology. Proc Natl Acad Sci U S A (1986) 2.45
Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. J Exp Med (1967) 2.41
Antigenicity of some new synthetic polypeptides and polypeptidyl gelatins. Biochem J (1964) 2.40
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron (1997) 2.33
Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A (1992) 2.31
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol (1991) 2.27
Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci U S A (1966) 2.25
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline. J Biol Chem (1968) 2.19
Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development (1991) 2.16
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett (2001) 2.15
The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem (1999) 2.13
Immunological studies with synthetic polypeptides. Adv Immunol (1966) 2.10
Regulation of cell proliferation by epidermal growth factor. CRC Crit Rev Biochem (1983) 2.09
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
Modified stock-eye ocular prosthesis. J Prosthet Dent (1985) 2.03
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron (1995) 2.02
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Neu and its ligands: from an oncogene to neural factors. Bioessays (1993) 2.00
Developmental expression of c-kit, a proto-oncogene encoded by the W locus. Development (1990) 1.99
Antigenicity: some molecular aspects. Science (1969) 1.98
The basic biology of HER2. Ann Oncol (2001) 1.97
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther (1999) 1.96
Epidermal growth factor induces electrically silent Na+ influx in human fibroblasts. J Biol Chem (1982) 1.96
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene (2001) 1.95
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J (1992) 1.93
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem (1994) 1.88
Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc Natl Acad Sci U S A (1981) 1.87
Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis (2007) 1.86
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem (1998) 1.81
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry (1990) 1.81
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene (2007) 1.79
A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene (2006) 1.78
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
The nature of the antigenic determinant in a genetic control of the antibody response. J Exp Med (1969) 1.74
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
Separation of multiple isomers of inositol phosphates formed in GH3 cells. Biochem J (1987) 1.73
Rotational diffusion of epidermal growth factor complexed to cell surface receptors reflects rapid microaggregation and endocytosis of occupied receptors. Proc Natl Acad Sci U S A (1981) 1.72
Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Neuron (1995) 1.70
Regulation of antibody response by cells expressing histamine receptors. J Exp Med (1972) 1.70
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
Antigen design and immune response. Harvey Lect (1973) 1.67
Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci U S A (1971) 1.67
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol (1995) 1.63
Circadian variation of symptomatic paroxysmal atrial fibrillation. Data from almost 10 000 episodes. Eur Heart J (1999) 1.63
Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem (1998) 1.62